drugset
drugset / Trial / NCT00476645

Fulvestrant in Hormone Refractory Prostate Cancer

NCT00476645 ↗

Phase 2 Completed 10 enrolled Stanford University AstraZeneca · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if treatment with fulvestrant leads to a slowing of tumor progression in patients who have developed androgen-independent (AIPC) or hormone-refractory prostate cancer (HRPC) and who have a rising serum prostate specific antigen (PSA).

Timeline

Start
2006-09
Primary completion
2009-09
Completion
2009-12

Publications

  • Results Srinivas S, Harshman LC, Feldman D. "Effect of fulvestrant on PSA doubling time in patients with castration-resistant prostate cancer (CRPC)." JCO. Annual Meeting, ASCO 2010. 20 May 2010;28(15-suppl)(abs e15112).

Drugs

EvaluationDrugModalityDoseRoute
Subject Fulvestrant Small molecule 250 mg Intramuscular

Indications

prostate cancer